95 - Advances and Controversies in Orthopedic Infections: A Multidisciplinary Discussion

Thursday, October 17, 2024

3:15 PM – 4:30 PM US PT

Location: Petree D

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Interactive Moderator(s)

Krishna Rao, MD, MS

Associate Professor
University of Michigan
Ann Arbor, MI, United States
Gregory Schrank, MD MPH (he/him/his)

Assistant Professor of Medicine
University of Maryland School of Medicine
Baltimore, Maryland, United States

Slides

Panelist(s)

Robin Patel, MD (she/her/hers)

Professor
Mayo Clinic
Rochester, MN, United States
Sandra Nelson, MD (she/her/hers)

Director, Musculoskeletal Infectious Disease and OPAT Programs Inpatient Clinical Director
Division of Infectious Diseases
Massachusetts General Hospital
Boston, MA, United States
Derek Amanatullah, MD/PhD (he/him/his)

Associate Professor
Stanford University

Disclosure(s):

Krishna Rao, MD, MS: Merck and Company, Inc.: Grant/Research Support; Rebiotix Inc.: Advisor/Consultant; Seres Therapeutics: Advisor/Consultant; Summit pharmaceuticals: Advisor/Consultant

Gregory M. Schrank, MD MPH: EnSenSys, LLC: Grant/Research Support (Ongoing)

Robin Patel, MD: a patent on Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, a: See above; MicuRx Pharmaceuticals and BIOFIRE: Grant/Research Support; PhAST, Day Zero Diagnostics, Abbott Laboratories, Sysmex, DEEPULL DIAGNOSTICS, S.L., Netflix, Oxford Nanopore Technologies and CARB-X: Advisor/Consultant; Up-to-Date and the Infectious Diseases Board Review Course.: Honoraria

Sandra B. Nelson, MD: No financial relationships to disclose

Derek F. Amanatullah, MD/PhD: Depuy-Synthes (a Johnson & Johnson company): Advisor/Consultant (Ongoing); Medacta: Advisor/Consultant (Ongoing); Peptologics: Advisor/Consultant (Ongoing); WellBeam: Advisor/Consultant (Ongoing), Stocks/Bonds (Private Company) (Ongoing)

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe the pros and cons of next generation sequencing methods for detection of orthopaedic infections;
recognize several treatment considerations other than antibiotics in managing orthopaedic infections;
explain the role of antimicrobial prophylaxis in orthopaedic surgery.